Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RUN and FYVE domain-containing protein 1 (RUFY1)
- Target
- RUFY1
- Molecular classification
- Adaptor protein, Endosomal trafficking protein, Zinc finger protein (FYVE-type domain), Effector protein, Other (contains RUN and FYVE domains but not classified as an enzyme, transporter, or classical receptor)
01
Overview
RUN and FYVE domain-containing protein 1 (RUFY1) is an adaptor protein that contains a RUN domain (important for interaction with small GTPases of the Rab and Rap families) and a FYVE-type zinc finger domain (which binds specifically to phosphatidylinositol-3-phosphate [PI3P]). RUFY1 regulates early endosomal trafficking, facilitator of endosome tethering and fusion, and retrieval of proteins from endosomes to the trans-Golgi network through interactions with the dynein-dynactin complex. RUFY1 has functional links to neurodegenerative diseases, cancer, and immune regulation, primarily due to its role in orchestrating cytoskeletal and vesicular dynamics[1][3][4][5]. Its dysfunction or altered expression can impact cellular homeostasis and contribute to pathological processes, particularly those involving impaired trafficking, autophagy, and cell migration. RUFY1 is one member of a small family of RUN and FYVE domain-containing proteins involved in similar trafficking and signaling functions.
- Other names
- RURUN and FYVE domain containing protein 1RUN and FYVE domain containing 1RUFY1_HUMANQ96T51
02
Mechanism of action
Not applicable; there are no approved drugs directly targeting RUFY1 as of now.
03
Biological functions
Endosomal cargo sortingProtein trafficking, specifically early/recycling endosome tethering and fusionInteracts with small GTPases (Rab4, Rab5, Rab14)Regulates trans-Golgi network retrievalSelf-assembly for endolysosome/autophagosome function in oocytes
04
Disease associations
Cancer (frequent mutation, role in cell migration and trafficking)Neurodegenerative disease (altered expression linked to neuronal deficit)Hereditary spastic paraplegia (HSP72A, Spastic Paraplegia 14, Autosomal Recessive)Immunity and inflammation (regulation by microRNA miR-155, involvement in immune cell trafficking)
05
Safety considerations
No direct therapeutic safety concerns have been described for targeting RUFY1; general challenges may include impacts on cellular trafficking and homeostasis, especially in neurons and immune cells
Beyond the preview
Go deeper on RUN and FYVE domain-containing protein 1 (RUFY1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RUN and FYVE domain-containing protein 1 (RUFY1).